All In Biotech

Drug Trial Radar · NCT03829254

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Jun 17, 2019

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
NuCana plcAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, dose-escalation and expansion study of NUC-7738 administered by intravenous infusion as a monotherapy and in combination with pembrolizumab. In Phase I, NUC-7738 monotherapy is evaluated across two administration schedules (weekly or fortnightly) in a dose-escalation design in patients with advanced solid tumours. The main objectives are to assess the safety and tolerability of NUC-7738, in addition to establishing the Maximum Tolerated Dose (MTD) and dose administration schedule of NUC-7738 for further exploration in the Phase II part of the study. In Phase II, the selected dose and designated dosing schedule will be further evaluated in dose-confirmation expansion cohorts enrolling a total of approximately 40 additional patients with advanced solid tumours. Based on emerging data, approximately 6 patients with cutaneous melanoma will be enrolled to these expansion cohorts and will receive NUC-7738 monotherapy. A further cohort will assess NUC-7738 in combination with pembrolizumab in approximately 6-12 patients with cutaneous melanoma. Based on efficacy signals observed in the initial melanoma combination cohort, a further expansion cohort will be initiated to expand to a total of 40 patients to allow a powered analysis. In addition, 12 patients with lymphoma (with potential expansion to a total of 25 patients) may be enrolled to receive NUC-7738 monotherapy.

Conditions

  • Advanced Cancer
  • Lymphoma
  • Solid Tumor
  • Melanoma

Interventions

  • NUC-7738Drug

    NUC-7738

  • PembrolizumabDrug

    Pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with dose-limiting toxicitiesTime frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
  2. Number of patients with treatment-emergent adverse events (CTCAE v5.0)Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
  3. Number of patients with clinically significant laboratory changes (CTCAE v5.0)Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
  4. Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
  5. MTD for NUC-7738 administered via weekly and fortnightly dosing schedules in patients with advanced solid tumoursTime frame: Until completion of Phase I (an average of 1 year)
  6. Percentage change from baseline in tumour sizeTime frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
  7. Objective response rate (ORR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
  8. Duration of response (DoR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
  9. Disease control rate (DCR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
  10. Duration of stable disease (DoSD)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
  11. Progression free survival (PFS)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital)

    Cambridge, United Kingdom · Recruiting

  • Edinburgh Cancer Centre, Western General Hospital

    Edinburgh, United Kingdom · Recruiting

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • University College London Hospital

    London, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Freeman Hospital

    Newcastle, United Kingdom · Recruiting

  • Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom · Recruiting

  • Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital

    Preston, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.